Please use this identifier to cite or link to this item:
Title: Recent advances in the management of type 2 diabetes mellitus: a review
Authors: Srinivasan, B.T.
Jarvis, J.
Khunti, K.
Davies, Melanie J.
First Published: Oct-2008
Publisher: BMJ Publishing Group
Citation: Postgraduate Medical Journal, 2008, 84 (996), pp. 524-531.
Abstract: Type 2 diabetes mellitus (T2DM) is a progressive disorder caused by a combination of insulin resistance and β cell dysfunction. It is associated with an increased and premature risk of cardiovascular disease as well as specific microvascular complications such as retinopathy, nephropathy and neuropathy. In the last 5 years new glucose lowering drugs acting on novel pathways have been developed, licensed and launched, such as the glucagon-like peptide (GLP-1) agonists (exenatide) and dipeptidyl peptidase (DPP-IV) inhibitors such as sitagliptin and vildagliptin. This review looks at these new agents in terms of their mode of action, pharmacokinetics and use in clinical practice. This review also includes new agents in the area of weight loss that may have a positive effect for glucose management—for example, rimonabant.
ISSN: 0032-5473
Type: Article
Description: This paper was published as Postgraduate Medical Journal, 2008, 84 (996), pp. 524-531. It is available from Doi: 10.1136/pgmj.2008.067918
Metadata only entry
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.